Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Savara Inc. (NASDAQ:SVRA) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.00.

Several brokerages recently weighed in on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Savara Stock Performance

NASDAQ SVRA opened at $5.42 on Friday. Savara has a fifty-two week low of $3.34 and a fifty-two week high of $7.01. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -9.34 and a beta of 0.25. The business has a fifty day moving average of $5.50 and a 200-day moving average of $5.45. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, analysts predict that Savara will post -0.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock worth $3,564,000 after acquiring an additional 320,572 shares during the period. Deutsche Bank AG purchased a new position in shares of Savara during the 2nd quarter worth $5,328,000. Orbimed Advisors LLC purchased a new position in shares of Savara during the 1st quarter worth $3,467,000. Walleye Capital LLC acquired a new stake in shares of Savara during the second quarter worth $1,532,000. Finally, Seven Fleet Capital Management LP boosted its holdings in shares of Savara by 371.1% during the first quarter. Seven Fleet Capital Management LP now owns 295,688 shares of the company’s stock worth $1,614,000 after purchasing an additional 232,926 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.